Newer drug sales lift Eli Lilly 2nd-qtr results, beating estimates

26 July 2016

US pharma major Eli Lilly (NYSE: LLY) reported better than expected second-quarter 2016 financial results. Revenue rose 9% to $5.4 billion, topping Wall Street estimates of $5.15 billion.

Lilly said net income for the quarter increased 24.5% to $747.7 million, or $0.71 per share. Excluding special items, including restructuring charges, Lilly earned $0.86 per share, in line with the average analyst estimate, according to Thomson Reuters. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $0.85 per share. Lilly’s shares were up 1.37% to $83.10 in pre-market trading this morning, after the financials were announced.

The company expects full-year earnings to be in the range of $3.50 to $3.60 and revenue to be between $20.6 billion and $21.1 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK